Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery

Head and neck cancer care, including tumors of the mouth, nose, throat and voice box, often requires radiation for cure to be achieved. Despite advances in radiation, 40% to 60% of patients experience a significant dry mouth (xerostomia) following radiotherapy. Several factors are associated with severe xerostomia including older age, advanced stage disease and tumor location. Currently, no pragmatic treatment strategy exists to reduce the risk of radiation-related xerostomia in patients with head and neck cancer. The investigators propose the use of a botulinum neurotoxin injected into the at-risk salivary glands before radiation as a strategy to preserve salivary gland function during radiation treatments and reduce xerostomia.

NCT Number	NCT06530524
Lead Sponsor	Sir Mortimer B. Davis - Jewish General Hospital Collaborators: Lady Davis Institute, McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions	Head Neck Cancer, Xerostomia Following Radiotherapy
Enrollment	50 participants
Start Date	2024-10-01
Primary Completion	2026-10-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2024-07-31